MedTrace Logo

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

NCT05686642 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-30

No results posted yet for this study

Summary

This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

LT3001 Drug:high dose

Administered by intravenous infusion.

DRUG

Placebo

Administered by intravenous infusion.

DRUG

LT3001 Drug:low dose

Administered by intravenous infusion.

Sponsors & Collaborators

  • Shanghai Pharmaceuticals Holding Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-06
Primary Completion
2026-12-10
Completion
2026-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686642 on ClinicalTrials.gov